InflaRx NV (FRA:IF0)
€ 1.35 0 (0%) Market Cap: 85.25 Mil Enterprise Value: 2.44 Mil PE Ratio: 0 PB Ratio: 0.89 GF Score: 32/100

Inflarx NV at Raymond James Human Health Innovation Conference (Virtual) Transcript

Jun 23, 2021 / 02:00PM GMT
Release Date Price: €2.4 (-8.54%)
Steve Seedhouse
Raymond James Financial - Analyst

Well, good morning and welcome, everyone, to the next session at the Raymond James Human Health Innovation Conference. I am Steve Seedhouse. It really is a pleasure for me to welcome the next participating company at our conference, InflaRx. InflaRx is a biotech company developing an anti-C5a antibody, vilobelimab or IFX-1, formally for inflammatory immune disorders. And I'm joined by, of course, CEO, Niels Riedemann; and Chief Strategy Officer, Jordan Zwick; and really looking forward to our virtual fireside chat.

So I would just also mention that listeners are invited to submit questions if you'd like via OpenExchange or you can email me directly.

Questions & Answers

Steve Seedhouse
Raymond James Financial - Analyst

But with that, would like to just hop right into it. And Niels, I wanted to start with your Hidradenitis Suppurativa program. Talk about basically the latest update, which was essentially that the FDA remains committed to HiSCR endpoint, which is what you used in your Phase II

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot